What is ImmunityBio, Inc.'s impairment charges?

ImmunityBio, Inc. (IBRX) reported impairment charges of $0 in Q4 2025.

What is the long-term trend for ImmunityBio, Inc.'s impairment charges?

Over 3 years (2022 to 2025), ImmunityBio, Inc.'s impairment charges has grown at a -100.0% compound annual growth rate (CAGR), from $681K to $0.

What does impairment charges mean?

Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.

ImmunityBio, Inc. IBRX Impairment Charges

Discontinued — last reported Q4 '25

Impairment Charges at other companies

IncyteINCY

$23.21M—

Kymera TherapeuticsKYMR

——

Segments

By segment

See full

Segment Reporting$0—

Other financials

Income statement

See full

Revenue$44.2M+168%

Gross profit$44.0M+167%

Operating income-$69.8M-8.3%

Net income-$632.8M-388%

EPS (diluted)-$0.62-313%

Balance sheet

See full

Cash & equivalents$205.2M+238%

Total debt$445.4M+32.2%

Total equity-$870.0M-47.1%

Total assets$646.6M+113%

Cash flow

See full

Operating cash flow-$75.4M+12.3%

CapEx$1.8M+58.4%

Free cash flow-$77.1M+11.4%

Valuation

See full

Market cap$7.71B+208%

Enterprise value$7.95B+187%

P/S54.7×-25.4×

Profitability

See full

Gross margin99.3%-0.5pp

Operating margin-185.4%-83.3pp

Net margin-606.2%-212pp

FCF margin-212%-95.8pp

Returns & leverage

See full

Return on equity-119.3%—

Debt / equity0.1×—

Current ratio6.7×+4.4×

Where this comes from

Reported directly by ImmunityBio, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill.

The official record: ImmunityBio, Inc.’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →

Ask your AI about ImmunityBio, Inc.'s impairment charges.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is ImmunityBio, Inc.'s impairment charges?: ImmunityBio, Inc. (IBRX) reported impairment charges of $0 in Q4 2025.
What is the long-term trend for ImmunityBio, Inc.'s impairment charges?: Over 3 years (2022 to 2025), ImmunityBio, Inc.'s impairment charges has grown at a -100.0% compound annual growth rate (CAGR), from $681K to $0.
What does impairment charges mean?: Write-downs of long-lived assets (excluding goodwill) when their carrying value exceeds fair value, including property, equipment, right-of-use assets, and other tangible assets.